Zymeworks Inc. (ZYME)

Market Cap	973.93M
Revenue (ttm)	62.20M
Net Income (ttm)	-113.67M
Shares Out	68.88M
EPS (ttm)	-1.52
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	730,482
Open	13.24
Previous Close	13.58
Day's Range	13.11 - 14.15
52-Week Range	7.97 - 17.70
Beta	1.12
Analysts	Buy
Price Target	19.17 (+35.57%)
Earnings Date	Oct 31, 2024

About ZYME

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 28, 2017
• Employees: 278
• Stock Exchange: NASDAQ
• Ticker Symbol: ZYME
• Website: https://www.zymeworks.com

Analyst Forecast

According to 6 analysts, the average rating for ZYME stock is "Buy." The 12-month stock price forecast is $19.17, which is an increase of 35.57% from the latest price.

Price Target

$19.17

(35.57% upside)

Analyst Consensus: Buy